An in vitro and in vivo study of electrospun polyvinyl alcohol/chitosan/sildenafil citrate mat on 3D-printed polycaprolactone membrane as a double layer wound dressing.

Double-layer dermal substitutes (DS) generally provide more effective therapeutic outcomes than single-layer substitutes. The architectural design of DS incorporates an outer layer to protect against bacterial invasions and maintain wound hydration, thereby reducing the risk of infection and the frequency of dressing changes. Moreover, the outer layer is a mechanical support for the wound, preventing undue tension in the affected area. A 3D-printed polycaprolactone (PCL) membrane was utilized as the outer layer to fabricate DS wound dressing. Simultaneously, a polyvinyl alcohol/chitosan/sildenafil citrate (PVA/CS/SC) scaffold was electrospun onto the PCL membrane to facilitate cellular adhesion and proliferation. Scanning electron microscopy (SEM) analysis of the PCL filaments revealed a consistent cross-sectional surface and structure, with an average diameter of 562.72 ±â€¯29.15 µm. SEM results also demonstrated uniform morphology and beadless structure for the PVA/CS/SC scaffold, with an average fiber diameter of 366.77 ±â€¯1.81 nm for PVA/CS. The addition of SC led to an increase in fiber diameter while resulting in a reduction in tensile strength. However, drug release analysis indicated that the SC release from the sample can last up to 72 h. Animal experimentation confirmed that DS wound dressing positively accelerated wound closure and collagen deposition in the Wistar rat skin wound model.

A bifunctional electrospun nanocomposite wound dressing containing surfactin and curcumin: In vitro and in vivo studies.

A double-nozzle electrospinning technique was adopted in the present study to yield a novel bifunctional wound dressing composed of curcumin (Cur) and surfactin (Sur)-loaded poly(ε-caprolactone) (PCL)-gelatin (Gel). To comprehensively unveil the effect of both composition and drug molecules on the applicability, different dressings composed of PCL, Gel, and combination of the polymers with the drug molecules were fabricated. Besides the physicochemical properties, the in vitro and in vivo biological properties of prepared wound dressings were assessed. The results showed that increasing in the Cur from 0 to 3% (w/w) and Sur from 0 to 0.2 mg/mL caused a decrease in the elastic modulus on the one hand. On the other hand, the tensile strength and elongation at break experienced an increase in their values. The wettability, swelling capacity, and degradation rate of PCL improved significantly when both Gel and the drug molecules had been added. The dressings encompassing Sur (0.2 mg/mL) exhibited an excellent antibacterial activity after 24 h (>99%). Moreover, a sustained release of Cur up to 14 days was obtained. The in vitro cell compatibility tests implied a desirable result for all dressings without taking the composition into consideration. To complement the in vitro studies, the PCL/0.2Sur-Gel/3%Cur dressing was further assessed in vivo and the results revealed a significant improvement in the healing rate compared to control groups proofing its great potential for accelerated wound healing applications.

Electrospun Polycaprolactone/lignin-based Nanocomposite as a Novel Tissue Scaffold for Biomedical Applications.

BACKGROUND: Biopolymer scaffolds have received great interest in academic and industrial environment because of their supreme characteristics like biological, mechanical, chemical, and cost saving in the biomedical science. There are various attempts for incorporation of biopolymers with cheap natural micro- or nanoparticles like lignin (Lig), alginate, and gums to prepare new materials with enhanced properties. METHODS: In this work, the electrospinning (ELS) technique as a promising cost-effective method for producing polymeric scaffold fibers was used, which mimics extracellular matrix structure for soft tissue engineering applications. Nanocomposites of Lig and polycaprolactone (PCL) scaffold produced with ELS technique. Nanocomposite containings (0, 5, 10, and 15 wt.%) of Lig were prepared with addition of Lig powder into the PCL solution while stirring at the room temperature. The bioactivity, swelling properties, morphological and mechanical tests were conducted for all the samples to investigate the nanocomposite scaffold features. RESULTS: The results showed that scaffold with 10 wt.% Lig have appropriate porosity, biodegradation, minimum fiber diameter, optimum pore size as well as enhanced tensile strength, and young modulus compared with pure PCL. Degradation test performed through immersion of samples in the phosphate-buffer saline showed that degradation of PCL nanocomposites could accelerate up to 10% due to the addition of Lig. CONCLUSIONS: Electrospun PCL-Lig scaffold enhanced the biological response of the cells with the mechanical signals. The prepared nanocomposite scaffold can choose for potential candidate in the biomedical science.

Fabrication of poly hydroxybutyrate-polyethylene glycol-folic acid nanoparticles loaded by paclitaxel.

In this study drug (paclitaxel)-loaded nanoparticles of poly hydroxybutyrate-polyethylene glycol-folic acid (PHB-PEG-FOL) were prepared by using an oil-in-water (O/W) emulsion-solvent evaporation method. The functionalization and conjugation steps in the chemical synthesis were confirmed using Fourier transform infrared (FTIR) and nuclear magnetic resonance tests ((1)H NMR). Morphology of nanoparticles was evaluated by scanning electron microscopy (SEM). Nanoparticles were characterized by particle size analyzer. Between two samples containing drug, the lower doses showed more homogeneous distribution, and the lowest aggregation. The drug release profiles showed a two-phase release including initial rapid release and a continuous release. MG63 cells were used to evaluate cytotoxicity. The cytotoxicity of PHB-PEG-FOL nanoparticles with drug against cancer cells was much higher and longer than free drug sample. These nanoparticles were successfully synthesized as a novel system for targeted drug delivery against cancer cells.